Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients

Clinical and Experimental Nephrology

Volumn 18, Issue 6, 2014, Pages 961-967

  Alpay, Nadir ^a   Ozkok, Abdullah ^b   Caliskan, Yasar ^a   Akagun, Tulin ^a   Cinar, Suzan Adın ^c   Deniz, Gunnur ^c   Sariyar, Muzaffer ^d   Yildiz, Alaattin ^a,d  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d International Hospital Istanbul   (Turkey)

Author keywords

Calcineurin inhibitors; Everolimus; Monocyte chemoattractant protein; Neutrophil gelatinase associated lipocalin; Pulse wave velocity; Transforming growth factor

Indexed keywords

C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA; URIC ACID; ACUTE PHASE PROTEIN; CCL2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; RAPAMYCIN;

ADULT; AGE; ARTICLE; AUGMENTATION INDEX; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY TUBULE DAMAGE; MALE; NEPHRITIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; FIBROSIS; GRAFT REJECTION; KIDNEY ARTERY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ACUTE-PHASE PROTEINS; ADULT; CALCINEURIN INHIBITORS; CHEMOKINE CCL2; FEMALE; FIBROBLAST GROWTH FACTORS; FIBROSIS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; LIPOCALINS; MALE; MIDDLE AGED; NEPHRITIS; PROTO-ONCOGENE PROTEINS; PULSE WAVE ANALYSIS; RENAL ARTERY; RISK FACTORS; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANT RECIPIENTS;

EID: 84919839224     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-0939-4     Document Type: Article

References (44)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12.
2. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033–6.
3. Paul LC. Chronic allograft nephropathy: an update. Kidney Int. 1999;56(3):783–93.
4. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int. 1996;49:518–24.
5. Joannidès R, Monteil C, de Ligny BH, Westeel PF, Iacob M, Thervet E, Barbier S, Bellien J, Lebranchu Y, Seguin SG, Thuillez C, Godin M, Etienne I. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transpl. 2011;11(11):2414–22.
6. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens. 2008;26(11):2213–9.
7. Yong K, Nguyen HD, Hii L, Chan DT, Boudville N, Messineo A, Lim EM, Dogra GK, Lim WH. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation. Am J Hypertens. 2013.
8. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transpl. 2004;4:1776–85.
9. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transpl. 2005;20(11):2517–23.
10. Stallone G, Di Paolo S, Schena A, Infante B, Grandiliano G, Battaglia M, Gesualdo L, Scehna FP. Early withdrawal of cyclosporine improves 1 year kidney graft structure and function in sirolimus treated patients. Transplantation. 2003;75:998–1003.
11. Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutierrez JA, Henriques AC, Pinto JR, Garcia J, Morales JM, Gomez JM, Arias M. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation. 2004;78:1312–8.
12. Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001;38:932–7.
13. Laurent S, Cockcroft J, Van BL, Boutouyrie P, Giannattasio C, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605.
14. Weber T, Ammer M, Rammer M, Adji A, O’rourke MF, et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens. 2009;27:1624–30.
15. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–33.
16. Klintmalm G, Bohman SO, Sundelin B, Wilczek H. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet. 1984;2:950–4.
17. Farnsworth A, Hall BM, Duggin GG, Horvath JS, Tiller DJ. Interstitial fibrosis in renal allografts in patients treated with cyclosporin. Lancet. 1984;2:1470–1.
18. Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M. Kidney transplantation under FK 506. JAMA. 1990;264:63–7.
19. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J SurgPathol. 1993;17:60–68.
20. Lassila M. Interaction of cyclosporine A and the renin angiotensin system; new perspectives. Curr Drug Metab. 2002;3:61–71.
21. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-β and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int. 2002;62:2257–63.
22. Vieira JM Jr, Noronha IL, Malheiros DM, Burdmann EA. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-β expression with preserved renal blood flow. Transplantation. 1999;68:1746–53.
23. Feldman G, Kiely B, Martin N, Ryan G, McMorrow T, Ryan MP. Role for TGF-β in cyclosporine-induced modulation of renal epithelial barrier function. J Am Soc Nephrol. 2007;18:1662–71.
24. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331:1286–92.
25. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway. Kidney Int. 2006;70:1914–9.
26. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15:1–12.
27. Feldman G, Kiely B, Martin N, Ryan G, McMorrow T, Ryan MP. Role for TGF-β in cyclosporine-induced modulation of renal epithelial barrier function. J Am Soc Nephrol. 2007;18:1662–71.
28. Goc A, Choudhary M, Byzova TV, Somanath PR. TGFβ- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin [mTOR]. J Cell Physiol. 2011;226(11):3004–13.
29. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 2006;69(11):2029–36.
30. Kurdián M, Herrero-Fresneda I, Lloberas N, Gimenez-Bonafe P, Coria V, Grande MT, Boggia J, Malacrida L, Torras J, Arévalo MA, González-Martínez F, López-Novoa JM, Grinyó J, Noboa O. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One. 2012;7(3):e32516.
31. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin [NGAL] as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595–605.
32. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation. 2004;78(3):434–41.
33. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J. Neutrophil gelatinase-associated lipocalin [NGAL]: a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol. 2010;25(5):889–97.
34. Dubiński B, Boratyńska M, Kopeć W, Szyber P, Patrzałek D, Klinger M. Activated cells in urine and monocyte chemotactic peptide-1 [MCP-1]–sensitive rejection markers in renal graft recipients. Transpl Immunol. 2008;18(3):203–7.
35. Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K, Nakao T, Okamura M, Kim S, Iwao H, Miura K. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation. 2002;74(6):784–91.
36. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17(11):2974–84.
37. Regateiro FS, Howie D, Cobbold SP, Waldmann H. TGF-β in transplantation tolerance. Curr Opin Immunol. 2011;23(5):660–9.
38. Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wüthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O, ZEUS Study Investigators. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transpl. 2012;12(6):1528–40.
39. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. ELITE Symph Study N Engl J Med. 2007;357(25):2562–75.
40. Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: The impact of non-immunologic factors. Kidney Int. 2002;62:1875–83.
41. Gómez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, Agudo-Conde C, Rodríguez-Sánchez E, Gómez-Sánchez L, Gómez-Sánchez M, García-Ortiz L. Relationship between uric acid and vascular structure and function in hypertensive patients and sex-related differences. Am J Hypertens. 2013;26(5):599–607.
42. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377(9768):837–47.
43. Perico N, Codreanu I, Caruso M, Remuzzi G. Hyperuricemia in kidney transplantation. Contrib Nephrol. 2005;147:124–31.
44. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100:657–66.